Cargando…

Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis

Cryptococcal meningoencephalitis is a rapidly lethal infection in immunocompromised patients. Induction regimens are usually administered for 2 weeks. The shortest effective period of induction therapy with liposomal amphotericin B (LAMB) is unknown. The pharmacodynamics of LAMB were studied in muri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lestner, Jodi, McEntee, Laura, Johnson, Adam, Livermore, Joanne, Whalley, Sarah, Schwartz, Julie, Perfect, John R., Harrison, Thomas, Hope, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444125/ https://www.ncbi.nlm.nih.gov/pubmed/28320715 http://dx.doi.org/10.1128/AAC.00090-17

Ejemplares similares

Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease
por: Nixon, Gemma L., et al.
Publicado: (2018)

Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis
por: Stott, Katharine E., et al.
Publicado: (2018)

Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
por: Jarvis, Joseph N, et al.
Publicado: (2022)

Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days
por: Livermore, Joanne, et al.
Publicado: (2014)

Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis
por: Kovanda, Laura L., et al.
Publicado: (2019)

Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis
por: Alvarez-Uria, Gerardo, et al.
Publicado: (2015)

Case report: Reversible encephalopathy associated with liposomal amphotericin B in a patient with cryptococcal meningitis
por: Luo, Si, et al.
Publicado: (2022)

Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance
por: Hope, William, et al.
Publicado: (2019)

Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis
por: Bicanic, Tihana, et al.
Publicado: (2015)

Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis
por: Stott, Katharine E, et al.
Publicado: (2022)

Safety of Single High-Dose Liposomal Amphotericin B for Induction Treatment of Cryptococcal Meningitis and Histoplasmosis in People With HIV: A Systematic Review and Meta-analysis
por: Kang, HeeEun, et al.
Publicado: (2023)

Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis
por: Rolfes, Melissa A., et al.
Publicado: (2015)

Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis
por: Stott, Katharine E., et al.
Publicado: (2018)

Paradoxical respiratory failure due to cryptococcal pneumonia after amphotericin B treatment for HIV-associated cryptococcal meningitis
por: Scriven, James E., et al.
Publicado: (2018)

Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice
por: Xu, Nan, et al.
Publicado: (2011)

A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2019)

An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2021)

A Novel Cryptococcal Meningitis Therapy: The Combination of Amphotericin B and Posaconazole Promotes the Distribution of Amphotericin B in the Brain Tissue
por: Yang, Ming, et al.
Publicado: (2020)

Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei
por: Le, Thuy, et al.
Publicado: (2019)

Short-Course Rather Than Low-Dose Amphotericin B May Exert Potential Influence on Mortality in Cryptococcal Meningitis Patients Treated With Amphotericin B Plus Flucytosine Alone or in Combination With Fluconazole
por: Xu, Lijun, et al.
Publicado: (2019)

869. Oral Encochleated Amphotericin B for Cryptococcal Meningitis: a Phase II Randomized Trial
por: Atukunda, Mucunguzi, et al.
Publicado: (2022)

Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2017)

Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis
por: Schell, Wiley A, et al.
Publicado: (2017)

What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis
por: Li, Yao, et al.
Publicado: (2020)

Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis
por: Giamberardino, Charles D., et al.
Publicado: (2022)

In Vitro Characterization of the Neurapheresis™ System for the Treatment of Cryptococcal Meningitis
por: Charalambous, Lefko, et al.
Publicado: (2017)

Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

Therapeutic and Prophylactic Effects of Amphotericin B Liposomes on Chronic Social Defeat Stress-Induced Behavioral Abnormalities in Mice
por: Lu, Jiashu, et al.
Publicado: (2022)

Targeted Propolis-Loaded Poly (Butyl) Cyanoacrylate Nanoparticles: An Alternative Drug Delivery Tool for the Treatment of Cryptococcal Meningitis
por: Thammasit, Patcharin, et al.
Publicado: (2021)

Standardized Electrolyte Supplementation and Fluid Management Improves Survival During Amphotericin Therapy for Cryptococcal Meningitis in Resource-Limited Settings
por: Bahr, Nathan C., et al.
Publicado: (2014)

Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease
por: Hope, William W., et al.
Publicado: (2017)

Liposomal amphotericin B—the present
por: Maertens, J, et al.
Publicado: (2022)

Liposomal amphotericin B—the past
por: Brüggemann, R J, et al.
Publicado: (2022)

Liposomal amphotericin B—the future
por: Hoenigl, M, et al.
Publicado: (2022)

Immune correlates of HIV-associated cryptococcal meningitis
por: Tenforde, Mark W., et al.
Publicado: (2017)

Prevalence and Hospital Management of Amphotericin B Deoxycholate-Related Toxicities during Treatment of HIV-Associated Cryptococcal Meningitis in South Africa
por: Meiring, Susan, et al.
Publicado: (2016)

Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus
por: Negri, Clara E, et al.
Publicado: (2018)

Disseminated cryptococcal infection in an immunocompetent patient treated with short course induction therapy
por: Parry, Alice, et al.
Publicado: (2020)

Cryptococcal meningitis: A neglected NTD?
por: Molloy, Síle F., et al.
Publicado: (2017)

Molecular mechanisms of cryptococcal meningitis
por: Liu, Tong-Bao, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_tecirbogd59cfkcujgmtsa3tj0